Reference
Mustafa SS, et al. The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab. Clinical Lymphoma, Myeloma & Leukemia 20: e590-e596, No. 9, Sep 2020. Available from: URL: http://doi.org/10.1016/j.clml.2020.04.006
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1821, 36 (2020). https://doi.org/10.1007/s40278-020-83156-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-83156-5